The objectives of this trial are to determine whether, in critically ill patients with severe acute kidney injury (AKI), randomization to accelerated initiation of renal replacement therapy (RRT), compared to standard initiation, leads to: 1. Improved survival (primary outcome); and 2. Recovery of kidney function (principal secondary outcome), defined as independence from RRT at 90 days
Acute kidney injury (AKI) is a common and devastating complication of critical illness. Once AKI is established, treatment is largely supportive and no intervention has been found to restore kidney function or improve overall survival. Renal replacement therapy (RRT), usually in the form of hemodialysis, is frequently needed to manage patients with severe AKI. Such patients have an in-hospital mortality that consistently exceeds 50% with delays in RRT initiation implicated as a possible contributor. A recent meta-analysis suggested that earlier initiation of RRT may improve survival, but this is based on data derived overwhelmingly from observational studies. The investigators recently completed a multi-centre randomized controlled pilot trial that confirmed the feasibility of allocating patients to two different strategies of RRT initiation. Patient recruitment and follow-up, as well as patient safety, were successfully demonstrated during the pilot phase of this research program. The optimal timing of RRT initiation is an existing knowledge gap and a clear priority for investigation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
3,019
In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops: serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI \> 72 hours following the time of randomization.
A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
All-cause Mortality.
Time frame: 90 days following study randomization.
RRT Dependence
Time frame: 90 days following study randomization.
Composite of Death or RRT Dependence.
Time frame: 90 days following study randomization.
Measurement of Estimated Glomerular Filtration Rate.
Time frame: 90 days following study randomization.
Measurement of Albuminuria.
Time frame: 90 days following study randomization.
Major Adverse Kidney Outcomes.
Defined as death, RRT dependence or sustained reduction in kidney function (defined as eGFR \< 75% baseline eGFR).
Time frame: 90 days following study randomization.
Mechanical Ventilation-free Days.
Time frame: Measured from randomization through day 28.
Vasoactive Therapy-free Days
Time frame: Measured from randomization through day 28.
ICU-free Days
Time frame: Measured from randomization through day 28.
Hospitalization-free Days
Time frame: Measured from randomization through day 90.
Death in ICU
Time frame: Measured in-hospital and at day 28.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Florida
Gainesville, Florida, United States
University of Kentucy
Lexington, Kentucky, United States
Mayo Clinic
Rochester, Minnesota, United States
Rhode Island Hospital
Providence, Rhode Island, United States
The Miriam Hospital
Providence, Rhode Island, United States
Ballarat Hospital
Ballarat, Australia
Flinder Medical Centre
Bedford Park, Australia
Bendigo Hospital
Bendigo, Australia
Eastern Hospital (Box Hill and Maroondah Hospital)
Box Hill, Australia
...and 95 more locations
EuroQoL EQ-5D-5L.
A measure of health-related quality of life and patient utility.
Time frame: Measured at day 90 and at day 365.
Health Care Costs.
Time frame: Measured from baseline through day 365.
Composite of Death or RRT Dependence.
Time frame: Measured at day 365.